Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2

Second generation insulin analogue — insulin glargine 300 UI/ml (GLA-300) — can provide an effective control of Diabetes Mellitus (DM) with minimal risk of hypoglycemic events and prevent of cardiovascular complications or events (CVS). Pharmacoeconomic comparison of most used insulins — GLA-300 and detemir (IDet) has been based on indirect treatment comparison in DM Type 2.
Materials and methods. Indirect treatment comparison was created according to published data of a real world evidence data for the treatment of DM Type 2 with GLA-300 and IDet, and common comparator — GLA-100 — has been used. Patients (%) who reached HbA1c target were indicated as an efficacy criteria. Odds ratios (OR) were calculated for clinical efficacy and severe hypoglycemia’s rate comparisons for GLA-300 and IDet. Direct (cost of annual treatment, hypoglycemia correction, CVS treatment), indirect medical costs as well as indirect costs (GDP loses) were calculated for GLA-300 and IDet strategies. Sensitivity analysis has been performed for confirmation of the base scenario results.
Results. GLA-300 has advantages vs IDet by efficacy and less risks of severe hypoglycemia (OR 1.27 CI 95 % 1.02; 1.58 and OR 0.72 CI 95 % 0.56; 0.88 accordingly). Probability of good control of DM Type 2 (based on target of HbA1c<7.0 %) was higher on 27 % in GLA-300. Costs of insulins, expenditures for CVS treatment and payment for temporary disability were similar for GLA-300 and IDet groups (for the one-year treatment period), in the same time in GLA-300 group the less expenditures for hypoglycemia were observed. Total expenditures were slightly less for GLA-300 on 3.7 % vs IDet.
Conclusion. GLA-300 and IDet have no economic advantages between groups in total costs, but GLA-300 has tended for economic benefi ts in compare with IDet in DM Type 2.

1. CDC COVID-1 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with Coronavirus disease 2019 - United States, February 12 - March 28,2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-386. https://doi.org/10.15585/mmwr.mm6913e2

2. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Diabetes Metab Syndr. 2020;14(4):513-517. https://doi.org/10.1016/j.dsx.2020.04.049

3. Popovich LD, Potapchik EG, Svetlichnaya SV. Ocenka ehkonomicheskih vygod ot realizacii ehff ektivnyh programm bor’by s saharnym diabetom 2-go tipa. Preprint WP8/2018/01. Gosudarstvennoe imunicipal’noe upravlenie. Moscow: 2018. (In Russ).

4. Dedov II. Lekarstvennoe obespechenie bol’nyh saharnym diabetom v neprostyh usloviyah. Farmacevticheskij vestnik. 2009;542(10);8. (In Russ).

5. Nedogoda SV, Sabanov AV, Barykina IN. Sravnitel’naya ocenka primeneniya analogov insulina u bol’nyh saharnym diabetom v Rossijskoj Federacii (analiticheskij obzor s elementami farmakoekonomicheskogo analiza). Eff ektivnaya farmakoterapiya. Endokrinologiya. Spetsvypusk “Diabetes Mellitus”. 2012;(1):4-10. (In Russ).

6. Rosenstock J, Cheng A, Ritzel R, et al. More similarities than diff erences testing Insulin Glargine 300 Units/mL versus Insulin Degludec 100 Units/mL in insulin-naive Type 2 Diabetes: Th e randomized Head-to-Head BRIGHT Trial. Diabetes Care. 2018;41(10):2147-2154. https://doi.org/10.2337/dc18-0559

7. Belousov DYu, Karpov OI. Economic aspects of second generation insulin analogs in diabetes mellitus type 2. Kachestvennaya klinicheskaya praktika. 2019;(1):4-11. (In Russ). https://doi.org/10.24411/2588-0519-2019-10053

8. Zhang J, He X, Wang K, et al. Association of severe hypoglycemia with all cause mortality and complications among patients with diabetes mellitus. Value in Health. 2019;22(S.3):S585.

9. Brennan A, Pollard D. A health economic and decision modelling analysis plan for an integrated database of over 100 clinical trials measuring hypoglycaemic attacks for people with diabetes: a hedmap for hypo resolve // Value in Health. 2019;22(S.3):S577.

10. Shestakova MV, Khalimov YuSh, Novikov VI, et al. Clinical and economic analysis of the use of insulin glargine in diabetes mellitus type 2. Klinicheskaya farmakologiya i terapiya. 2009;18(2):92-96. (In Russ).

11. Dedov II, Omelyanovsky VV, Shestakova MV, et al. Diabetes mellitus as an economic problem In Russian Federation. Diabetes Mellitus. 2016;19(1):30-43 (In. Russ). https://doi.org/10.14341/DM7784

12. Abitbol A, Brown RE, Jiandani D, et al. Real-World health outcomes of insulin glargine 300 U/mL vs insulin glargine 100 U/mL in adults with Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study. Can J Diabetes. 2019;43(7):504-509. e1.https://doi.org/10.1016/j.jcjd.2019.04.012

13. Bailey TS, Zhou FL, Gupta RA, et al. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Na?ve cohort study. Diabetes Obes Metab. 2019;21(7):1596-1605.https://doi.org/10.1111/dom.13693

14. Xie L, Wei W, Pan C, et al. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. Adv Ther. 2011;28(11):1000-1111. https://doi.org/10.1007/s12325-011-0074-5

15. Davis KL, Tangirala M, Meyers JL, Wei W. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy. Curr Med Res Opin. 2013;29(9):1083-91.https://doi.org/10.1185/03007995.2013.811403

16. Canadian Agency for Drugs and Technologies in Health (CADTH). Indirect treatment comparison (ITC)https://www.cadth.ca Ссылка активна на 10.02.2020.

17. Metodicheskie rekomendacii po provedeniyu nepryamyh sravnenij lekarstvennyh preparatov. FGBU «CEKKMP» Minzdrava Rossii; 2017. (In Russ). URL: https://rosmedex.ru/wp-content/uploads/2018/01/Metodicheskierekomendatsii-po-provedeniyu-nepryamyih-sravneniy-LP-2017-g..pdf Ссылка активна на 12.02.2020.

18. Pharmacoeconimcs and pharmacoepidemilogy - practice of the right decisions / Ed. VB Gerasimov, AL Khokhlov, OI Karpov. Moscow: Medicina; 2005. (In Russ).

19. Fletcher R, Fletcher S, Vagner E. Klinicheskaya epidemiologiya: Osnovy dokazatel’noj mediciny. Moscow: Media Sfera; 1998.

20. Pettus J, Roussel R, Liz Zhou F, et al. Rates of hypoglycemia predicted in patients with type 2 Diabetes on insulin glargine 300 U/ml versus first- and secondgeneration basal insulin analogs: The Real-World LIGHTNING Study. Diabetes Ther. 2019;10(2):617-633. https://doi.org/10.1007/s13300-019-0568-8

21. Kolbin AS, Kurilev AA, Balikina YuE, Proskurin MA, Karpov OI. Economic evaluation of insulin therapy intensification for effective and safe control of Diabetes Mellitus type 2. Kachestvennaya klinicheskaya praktika. 2019;(2):25-35. (In Russ). https://doi.org/10.24411/2588-0519-2019-10070

22. Laubner K, Molz K, Kerner W, et al. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51?964 patients from the German/Austrian DPV-wiss database. Diabetes Metab Res Rev. 2014;30(5):395-404. https://doi.org/10.1002/dmrr.2500

23. Belousov DYu, Karpov OI. Cost Estimate while Transferring Patients with Diabetes Mellitus from Insulin Glargine-100 to Insulin Glargine-300 in Real-Life Practice // Kachestvennaya klinicheskaya praktika. 2017;(3):4-15. (In Russ).

24. Gosudarstvennyi reestr predelnykh otpusknykh tsen. (In Russ). URL:https://grls.rosminzdrav.ru/Default.aspx Ссылка активна на 14.01.2020.

25. Predelnye razmery optovykh nadbavok i predelnye razmery roznichnykh nadbavok k tsenam na zhiznenno neobkhodimye i vazhneishie lekarstvennye preparaty ustanovlennye v subieektakh Rossiiskoi Federatsii. (In Russ). URL: https://fas.gov.ru/documents/684978 Ссылка активна на 11.02.2020.

26. Resolution of the Government of the Russian Federation No. 1683 of 16.12.2019 “O vnesenii izmenenii v nekotorye akty Pravitelstva Rossiiskoi Federatsii v chasti gosudarstvennoi registratsii i pereregistratsii predelnykh otpusknykh tsen na lekarstvennye preparaty vkliuchennye v perechen zhiznenno neobkhodimykh i vazhneishikh lekarstvennykh preparatov”. (In Russ). URL: http://static.government.ru/media/files/1riw7sArETmZp70rvcRLUywCOHOotEPk.pdf Ссылка активна на 13.03.2020.

27. Dedov II, Kalashnikova MF, Belousov DY, et al. Assessing routine healthcare pattern for type 2 diabetes mellitus In Russia: the results of рharmacoepidemiological study (FORSIGHT DM2) // Diabetes mellitus. - 2016. - Т. 19. - №6. - C. 443-456. https://doi.org/10.14341/DM8146. (In Russ). URL: https://dia-endojournals.ru/dia/article/view/8146. Ссылка активна на 20.01.2020

28. Decree of the Government of the Russian Federation No. 1506 of December 10, 2018 “O programme gosudarstvennykh garantii besplatnogo okazaniia grazhdanam meditsinskoi pomoshchi na 2019 god i na planovyi period 2020 i 2021 godov”. (In Russ). URL: http://government.ru/docs/35025, Ссылка активна на 01.11.2019.

29. Instrukciya po gruppirovke sluchaev, v tom chisle pravila ucheta klassifikacionnyh kriteriev, i podhodam k oplate medicinskoj pomoshchi v ambulatornyh usloviyah po podushevomu normativu finansirovaniya. (In Russ). URL: http://ffoms.ru/documents/the-orders-oms Ссылка активна на 20.01.2020.

30. Chen S, Hou X, Zhou X, et al. The long-term effectiveness of metabolic control on cardiovascular disease in patients with diabetes in a real-world health care setting - A prospective diabetes management study. Prim Care Diabetes. 2019pii: S1751-9918(19)30004-X. https://doi.org/10.1016/j.pcd.2019.09.006

31. Dannye Federal’noj sluzhby gosudarstvennoj statistiki. Srednemesyachnaya nominal’naya nachislennaya zarabotnaya plata rabotnikov v celom po ekonomike po sub»ektam Rossijskoj Federacii za 2000-2018 gg. (In Russ). URL: https://www.gks.ru/labor_market_employment_salaries Ссылка активна на 11.02.2020.

32. Ji L, Zhang P, Zhu D, et al. Comparative effectiveness and safety of different basal insulins in a real-world setting. Diabetes Obes Metab. 2017;19(8):1116-1126. https://doi.org/10.1111/dom.12920

33. Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD006383.https://doi.org/10.1002/14651858.CD006383.pub2

34. Pscherer S, Chou E, Dippel FW, et al. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis. Prim Care Diabetes. 2015;9(5):377-84.https://doi.org/10.1016/j.pcd.2015.01.011

35. Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300?U/ml in people with type 2 diabetes. Diabetes Technol Ther. 2016;18(4):252-257.https://doi.org/10.1089/dia.2015.0290.

36. Bailey TS, Wu J, Zhou FL, et al. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3). Diabetes Obes Metab. 2019;(21):2384-2393.https://doi.org/10.1111/dom.13818